Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma.

Baumann A, Buchberger AMS, Piontek G, Schüttler D, Rudelius M, Reiter R, Gebel L, Piendl G, Brockhoff G, Pickhard A.

Oncotarget. 2018 Jan 30;9(16):12769-12780. doi: 10.18632/oncotarget.24355. eCollection 2018 Feb 27.

2.

CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.

Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A.

Cell Death Dis. 2018 Jan 24;9(2):86. doi: 10.1038/s41419-017-0157-6.

3.

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations.

Garz AK, Wolf S, Grath S, Gaidzik V, Habringer S, Vick B, Rudelius M, Ziegenhain C, Herold S, Weickert MT, Smets M, Peschel C, Oostendorp RAJ, Bultmann S, Jeremias I, Thiede C, Döhner K, Keller U, Götze KS.

Oncotarget. 2017 Oct 16;8(65):108738-108759. doi: 10.18632/oncotarget.21877. eCollection 2017 Dec 12.

4.

Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.

Schuler E, Frank F, Hildebrandt B, Betz B, Strupp C, Rudelius M, Aul C, Schroeder T, Gattermann N, Haas R, Germing U.

Leuk Res. 2018 Feb;65:1-4. doi: 10.1016/j.leukres.2017.12.002. Epub 2017 Dec 5.

PMID:
29216536
5.

Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation.

Effenberger M, Bommert KS, Kunz V, Kruk J, Leich E, Rudelius M, Bargou R, Bommert K.

Oncotarget. 2017 Aug 24;8(49):85858-85867. doi: 10.18632/oncotarget.20691. eCollection 2017 Oct 17.

6.

Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.

Jacobs L, Habringer S, Slawska J, Huber K, Hauf E, Li Z, Refaeli Y, Schwaiger M, Rudelius M, Walch A, Keller U.

Oncotarget. 2017 Aug 24;8(45):78917-78929. doi: 10.18632/oncotarget.20551. eCollection 2017 Oct 3.

7.

Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.

Rudelius M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, Solimando AG, Beilhack A, Ott G, Rosenwald A.

Haematologica. 2018 Jan;103(1):116-125. doi: 10.3324/haematol.2017.177162. Epub 2017 Oct 27.

8.

JAM-A as a prognostic factor and new therapeutic target in multiple myeloma.

Solimando AG, Brandl A, Mattenheimer K, Graf C, Ritz M, Ruckdeschel A, Stühmer T, Mokhtari Z, Rudelius M, Dotterweich J, Bittrich M, Desantis V, Ebert R, Trerotoli P, Frassanito MA, Rosenwald A, Vacca A, Einsele H, Jakob F, Beilhack A.

Leukemia. 2018 Mar;32(3):736-743. doi: 10.1038/leu.2017.287. Epub 2017 Sep 28.

9.

First case of human peritoneal cysticercosis mimicking peritoneal carcinosis: necessity of laparoscopy and histologic assessment for the correct diagnosis.

Rudelius M, Brehm K, Poelcher M, Spinner C, Rosenwald A, da Costa CP.

JMM Case Rep. 2017 Jun 8;4(6):e005097. doi: 10.1099/jmmcr.0.005097. eCollection 2017 Jun.

10.

Overexpression of Insulin-Like Growth Factor-2 in Expanded Endothelial Progenitor Cells Improves Left Ventricular Function in Experimental Myocardial Infarction.

Demetz G, Oostendorp RAJ, Boxberg AM, Sitz W, Farrell E, Steppich B, Steinsiek AL, Rudelius M, Ott I.

J Vasc Res. 2017;54(6):321-328. doi: 10.1159/000479872. Epub 2017 Sep 27.

PMID:
28950284
11.

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach.

Werner RA, Weich A, Higuchi T, Schmid JS, Schirbel A, Lassmann M, Wild V, Rudelius M, Kudlich T, Herrmann K, Scheurlen M, Buck AK, Kropf S, Wester HJ, Lapa C.

Theranostics. 2017 Apr 5;7(6):1489-1498. doi: 10.7150/thno.18754. eCollection 2017.

12.

Primary skin manifestation of plasmoblastic lymphoma in an AIDS patient with long-term survival.

Todorova A, Zink A, Spinner CD, Schielein M, Vogelmann R, Weirich G, Rudelius M, Andres C, Traidl-Hoffmann C.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e428-e429. doi: 10.1111/jdv.14323. Epub 2017 Jul 3. No abstract available.

PMID:
28499061
13.

[11 C]Methionine emerges as a new biomarker for tracking active myeloma lesions.

Lapa C, Schreder M, Lückerath K, Samnick S, Rudelius M, Buck AK, Kortüm KM, Einsele H, Rosenwald A, Knop S.

Br J Haematol. 2018 Jun;181(5):701-703. doi: 10.1111/bjh.14696. Epub 2017 May 3. No abstract available.

PMID:
28466502
14.

RIG-I/MAVS and STING signaling promote gut integrity during irradiation- and immune-mediated tissue injury.

Fischer JC, Bscheider M, Eisenkolb G, Lin CC, Wintges A, Otten V, Lindemans CA, Heidegger S, Rudelius M, Monette S, Porosnicu Rodriguez KA, Calafiore M, Liebermann S, Liu C, Lienenklaus S, Weiss S, Kalinke U, Ruland J, Peschel C, Shono Y, Docampo M, Velardi E, Jenq RR, Hanash AM, Dudakov JA, Haas T, van den Brink MRM, Poeck H.

Sci Transl Med. 2017 Apr 19;9(386). pii: eaag2513. doi: 10.1126/scitranslmed.aag2513.

15.

Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.

Swarts DR, Rudelius M, Claessen SM, Cleutjens JP, Seidl S, Volante M, Ramaekers FC, Speel EJ.

Histopathology. 2017 Feb;70(3):412-422. doi: 10.1111/his.13096. Epub 2016 Nov 23.

PMID:
27701763
16.

USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.

Engel K, Rudelius M, Slawska J, Jacobs L, Ahangarian Abhari B, Altmann B, Kurutz J, Rathakrishnan A, Fernández-Sáiz V, Brunner A, Targosz BS, Loewecke F, Gloeckner CJ, Ueffing M, Fulda S, Pfreundschuh M, Trümper L, Klapper W, Keller U, Jost PJ, Rosenwald A, Peschel C, Bassermann F.

EMBO Mol Med. 2016 Aug 1;8(8):851-62. doi: 10.15252/emmm.201506047. Print 2016 Aug.

17.

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F.

Nat Med. 2016 Jul;22(7):735-43. doi: 10.1038/nm.4128. Epub 2016 Jun 13.

PMID:
27294876
18.

Cardiac Manifestation of Acute Lymphoblastic Leukemia.

Werner RA, Rudelius M, Thurner A, Higuchi T, Lapa C.

Clin Nucl Med. 2016 Jul;41(7):570-1. doi: 10.1097/RLU.0000000000001235.

PMID:
27088389
19.

Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.

Müller TA, Grundler R, Istvanffy R, Rudelius M, Hennighausen L, Illert AL, Duyster J.

Leukemia. 2016 Aug;30(8):1725-33. doi: 10.1038/leu.2016.72. Epub 2016 Apr 5.

PMID:
27046463
20.

Targeting protein kinase C in mantle cell lymphoma.

Rauert-Wunderlich H, Rudelius M, Ott G, Rosenwald A.

Br J Haematol. 2016 May;173(3):394-403. doi: 10.1111/bjh.13973. Epub 2016 Feb 23.

PMID:
26914495
21.

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.

Lapa C, Lückerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, Rudelius M, Kropf S, Buck AK, Ernestus RI, Wester HJ, Löhr M, Herrmann K.

Theranostics. 2016 Jan 25;6(3):428-34. doi: 10.7150/thno.13986. eCollection 2016.

22.

11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement.

Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jörg G, Samnick S, Herrmann K, Buck AK, Einsele H, Lückerath K.

Theranostics. 2016 Jan 1;6(2):254-61. doi: 10.7150/thno.13921. eCollection 2016.

23.

[68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer--initial experience.

Lapa C, Lückerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A, Samnick S, Pelzer T, Buck AK, Kropf S, Wester HJ, Herrmann K.

Oncotarget. 2016 Feb 23;7(8):9288-95. doi: 10.18632/oncotarget.7063.

24.

CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates.

Hartmann EM, Rudelius M, Burger JA, Rosenwald A.

Leuk Lymphoma. 2016;57(3):563-71. doi: 10.3109/10428194.2015.1068308. Epub 2015 Oct 12.

PMID:
26458057
25.

In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment.

Franke K, Vilne B, Prazeres da Costa O, Rudelius M, Peschel C, Oostendorp RA, Keller U.

Oncotarget. 2015 Sep 8;6(26):21827-39.

26.

The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells.

Rudelius M, Rauert-Wunderlich H, Hartmann E, Hoster E, Dreyling M, Klapper W, Ott G, Rosenwald A.

Haematologica. 2015 Nov;100(11):e458-61. doi: 10.3324/haematol.2015.127399. Epub 2015 Aug 6. No abstract available.

27.

Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes.

Erlmeier F, Feuchtinger A, Borgmann D, Rudelius M, Autenrieth M, Walch AK, Weirich G.

Histochem Cell Biol. 2015 Aug;144(2):147-56. doi: 10.1007/s00418-015-1324-4. Epub 2015 May 1.

PMID:
25929744
28.

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.

Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M.

Theranostics. 2015 Mar 1;5(6):618-30. doi: 10.7150/thno.11251. eCollection 2015.

29.

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.

Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U.

EMBO Mol Med. 2015 Apr;7(4):477-87. doi: 10.15252/emmm.201404698.

30.

The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum.

Momose S, Weißbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, Geissinger E, Staiger AM, Ott G, Rosenwald A.

Leukemia. 2015 Aug;29(8):1789-91. doi: 10.1038/leu.2015.34. Epub 2015 Feb 12. No abstract available.

PMID:
25673238
31.

Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.

Gewies A, Gorka O, Bergmann H, Pechloff K, Petermann F, Jeltsch KM, Rudelius M, Kriegsmann M, Weichert W, Horsch M, Beckers J, Wurst W, Heikenwalder M, Korn T, Heissmeyer V, Ruland J.

Cell Rep. 2014 Nov 20;9(4):1292-305. doi: 10.1016/j.celrep.2014.10.044. Epub 2014 Nov 13.

32.

Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis.

Baumann U, Fernández-Sáiz V, Rudelius M, Lemeer S, Rad R, Knorn AM, Slawska J, Engel K, Jeremias I, Li Z, Tomiatti V, Illert AL, Targosz BS, Braun M, Perner S, Leitges M, Klapper W, Dreyling M, Miething C, Lenz G, Rosenwald A, Peschel C, Keller U, Kuster B, Bassermann F.

Nat Med. 2014 Dec;20(12):1401-9. doi: 10.1038/nm.3740. Epub 2014 Nov 24.

PMID:
25419709
33.

GP130 activation induces myeloma and collaborates with MYC.

Dechow T, Steidle S, Götze KS, Rudelius M, Behnke K, Pechloff K, Kratzat S, Bullinger L, Fend F, Soberon V, Mitova N, Li Z, Thaler M, Bauer J, Pietschmann E, Albers C, Grundler R, Schmidt-Supprian M, Ruland J, Peschel C, Duyster J, Rose-John S, Bassermann F, Keller U.

J Clin Invest. 2014 Dec;124(12):5263-74. doi: 10.1172/JCI69094. Epub 2014 Nov 10.

34.

Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR / SphK1 crosstalk.

Schiefler C, Piontek G, Doescher J, Schuettler D, Mißlbeck M, Rudelius M, Haug A, Reiter R, Brockhoff G, Pickhard A.

Oncotarget. 2014 Oct 30;5(20):9877-88.

35.

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.

Hoellein A, Fallahi M, Schoeffmann S, Steidle S, Schaub FX, Rudelius M, Laitinen I, Nilsson L, Goga A, Peschel C, Nilsson JA, Cleveland JL, Keller U.

Blood. 2014 Sep 25;124(13):2081-90. doi: 10.1182/blood-2014-06-584524. Epub 2014 Aug 20.

36.

The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.

Pickhard A, Siegl M, Baumann A, Huhn M, Wirth M, Reiter R, Rudelius M, Piontek G, Brockhoff G.

Oncotarget. 2014 Jul 30;5(14):5428-38.

37.

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL.

Herrmann K, Buck AK, Schuster T, Abbrederis K, Blümel C, Santi I, Rudelius M, Wester HJ, Peschel C, Schwaiger M, Dechow T, Keller U.

Oncotarget. 2014 Jun 30;5(12):4050-9.

38.

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K.

Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27. No abstract available.

39.

Quantitative expression and localization of cysteine and aspartic proteases in human abdominal aortic aneurysms.

Lohoefer F, Reeps C, Lipp C, Rudelius M, Haertl F, Matevossian E, Zernecke A, Eckstein HH, Pelisek J.

Exp Mol Med. 2014 May 16;46:e95. doi: 10.1038/emm.2014.20.

40.

Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck.

Pickhard A, Gröber S, Haug AK, Piontek G, Wirth M, Straßen U, Rudelius M, Reiter R.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jun;117(6):733-42. doi: 10.1016/j.oooo.2014.02.005. Epub 2014 Feb 13.

PMID:
24726415
41.

Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.

Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT, Dechow T.

Oncogene. 2015 Jan 29;34(5):578-88. doi: 10.1038/onc.2013.592. Epub 2014 Feb 10.

PMID:
24509876
42.

An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma.

Engel K, Rudelius M, Meinel FG, Peschel C, Keller U.

BMC Hematol. 2014 Jan 16;14(1):2. doi: 10.1186/2052-1839-14-2.

43.

Central review of lymphoma diagnosis: still a prerequisite for best patient care in 2014?

Rudelius M, Rosenwald A.

Leuk Lymphoma. 2014 May;55(5):973-4. doi: 10.3109/10428194.2013.870340. Epub 2014 Jan 28. No abstract available.

PMID:
24295129
44.

[Unclear tumor under the upper eyelid].

Lukashevich M, Mayer C, Rudelius M.

Ophthalmologe. 2013 Aug;110(8):773-5. doi: 10.1007/s00347-013-2860-8. German. No abstract available.

PMID:
23695290
45.

Comparison of cyclic RGD peptides for αvβ3 integrin detection in a rat model of myocardial infarction.

Laitinen I, Notni J, Pohle K, Rudelius M, Farrell E, Nekolla SG, Henriksen G, Neubauer S, Kessler H, Wester HJ, Schwaiger M.

EJNMMI Res. 2013 May 11;3(1):38. doi: 10.1186/2191-219X-3-38.

46.

CD44 and OTP are strong prognostic markers for pulmonary carcinoids.

Swarts DR, Henfling ME, Van Neste L, van Suylen RJ, Dingemans AM, Dinjens WN, Haesevoets A, Rudelius M, Thunnissen E, Volante M, Van Criekinge W, van Engeland M, Ramaekers FC, Speel EJ.

Clin Cancer Res. 2013 Apr 15;19(8):2197-207. doi: 10.1158/1078-0432.CCR-12-3078. Epub 2013 Feb 26.

47.

Protein kinase c-β-dependent activation of NF-κB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.

Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ, Dürig J, Wagner M, Haferlach C, Kohlmann A, Schnittger S, Seifert M, Wanninger S, Zaborsky N, Oostendorp R, Ruland J, Leitges M, Kuhnt T, Schäfer Y, Lampl B, Peschel C, Egle A, Ringshausen I.

Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.

48.

High expression of crystallin αB represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells.

Volkmann J, Reuning U, Rudelius M, Häfner N, Schuster T, Becker V Ros A, Weimer J, Hilpert F, Kiechle M, Dürst M, Arnold N, Schmalfeldt B, Meindl A, Ramser J.

Int J Cancer. 2013 Jun 15;132(12):2820-32. doi: 10.1002/ijc.27975. Epub 2012 Dec 27.

49.

Symmetric multifocal bone marrow involvement diagnosed by whole-body magnetic resonance imaging in a patient with B lymphoblastic lymphoma.

Eichner R, Wörtler K, Essler M, Rudelius M, Peschel C, Ringshausen I, Götze K.

Ann Hematol. 2013 Jan;92(2):277-8. doi: 10.1007/s00277-012-1552-9. Epub 2012 Aug 19. No abstract available.

PMID:
22903509
50.

Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall.

Lohoefer F, Reeps C, Lipp C, Rudelius M, Zimmermann A, Ockert S, Eckstein HH, Pelisek J.

Int J Exp Pathol. 2012 Aug;93(4):252-8. doi: 10.1111/j.1365-2613.2012.00819.x.

Supplemental Content

Loading ...
Support Center